# The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

> **NCT03649724** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Weill Medical College of Cornell University** · enrollment: 180 (estimated)

## Conditions studied

- Alzheimer Disease
- Mild Cognitive Impairment

## Interventions

- **DRUG:** Placebo
- **DRUG:** Eligard 22.5Mg Suspension for Injection

## Key facts

- **NCT ID:** NCT03649724
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-27
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-08-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03649724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03649724, "The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03649724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*